Sana Biotechnology, Inc. Accrued Liabilities and Other Liabilities
Sana Biotechnology, Inc. (SANA) had Accrued Liabilities and Other Liabilities of $8.23 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccruedLiabilitiesAndOtherLiabilities · last filed 2026-08-10
- 2026-06-30: Accrued Liabilities and Other Liabilities $8.23M.
- 2026-03-31: Accrued Liabilities and Other Liabilities $8.12M.
- 2025-12-31: Accrued Liabilities and Other Liabilities $8.68M.
- 2025-09-30: Accrued Liabilities and Other Liabilities $7.99M.
| Period end | Accrued Liabilities and Other Liabilities |
|---|---|
| 2026-06-30 | $8.23M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $8.12M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $8.68M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $7.99M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $7.93M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $9.81M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $13.24M 10-K · filed 2026-03-03 |
| 2024-09-30 | $15.36M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $21.29M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $19.67M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $23.46M 10-K · filed 2025-03-17 |
| 2023-09-30 | $18.94M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $18.04M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $13.30M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $14.55M 10-K · filed 2024-02-29 |
| 2022-09-30 | $14.97M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $13.98M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $11.32M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $10.34M 10-K · filed 2023-03-16 |
| 2021-09-30 | $12.88M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $12.83M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $11.17M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $9.47M 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |